Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

[Preprint]. 2021 Mar 26:2021.01.27.21250619. Originally published 2021 Jan 29. [Version 3] doi: 10.1101/2021.01.27.21250619

PMC7852256.1; 2021 Jan 29
PMC7852256.3; 2021 Mar 26

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.

PMC Copyright notice

Figure 1. — Efficacy of Moderna and Pfizer-BioNTech vaccines against all infection, symptomatic disease and severe disease, derived from published studies and US FDA briefing documents [3,4,6,22–24]. (*) During the first 14 days following the first dose of vaccines, there was no statistically significant difference between the protection in the vaccinated and unvaccinated cohorts. (#) Conservatively assumed to be the same as efficacy against infection during the preceding 14 days (prior to the second dose). (†) Conservatively assumed to be the same as efficacy against severe disease during the preceding 14 days (prior to the second dose). (§) Assumed to be the same as efficacy against symptomatic COVID-19.